Abstract

There is little data on why glioblastomas (GBM) hemorrhage and how it may affect patient outcomes. The aim of this study was to investigate the mechanisms of hemorrhage in glioblastoma by examining molecular and genetic features by immunohistochemistry (IHC) and mRNA expression profiles in association with imaging and clinical outcomes. An observational retrospective cohort analysis was performed on 43 FFPE GBM tissue samples. MR images were assessed for the presence of hemorrhage and extent of resection. Specimens were examined for CD34 and CD105 expression using IHC. Tumor mRNA expression profiles were analyzed for 92 genes related to angiogenesis and vascularity. Forty-three specimens were analyzed, and 20 showed signs of hemorrhage, 23 did not. The average OS for patients with GBM with hemorrhage was 19.12 months (95% CI 10.39–27.84), versus 13.85 months (95% CI 8.85–18.85) in those without hemorrhage (p > 0.05). Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3. Hemorrhage in GBM was not associated with worsened OS. Increased expression of angiogenic factors and increased CD34 and CD105 IHC staining in tumors with hemorrhage suggests that increased hypoxia-induced angiogenesis and vessel density may play a role in glioblastoma hemorrhage. Characterizing tumors that are prone to hemorrhage and mechanisms behind the development of these hemorrhages may provide insights that can lead to the development of targeted, individualized therapies for glioblastoma.

Original languageEnglish (US)
Pages (from-to)35-44
Number of pages10
JournalJournal of Neuro-Oncology
Volume132
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Glioblastoma
Hemorrhage
Immunohistochemistry
Neoplasms
Messenger RNA
Staining and Labeling
Angiogenesis Inducing Agents
Molecular Biology
Cohort Studies

Keywords

  • Gene analysis
  • Glioblastoma
  • HIF1α
  • Hemorrhage
  • Vascularity

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Assessment of vascularity in glioblastoma and its implications on patient outcomes. / McGahan, Ben G.; Neilsen, Beth K.; Kelly, David Lee; McComb, Rodney D; Kazmi, S. A Jaffar; White, Matthew L; Zhang, Yan; Aizenberg Ansari, Michele R.

In: Journal of Neuro-Oncology, Vol. 132, No. 1, 01.03.2017, p. 35-44.

Research output: Contribution to journalArticle

@article{64037c646b40449b89161fac6b4b6836,
title = "Assessment of vascularity in glioblastoma and its implications on patient outcomes",
abstract = "There is little data on why glioblastomas (GBM) hemorrhage and how it may affect patient outcomes. The aim of this study was to investigate the mechanisms of hemorrhage in glioblastoma by examining molecular and genetic features by immunohistochemistry (IHC) and mRNA expression profiles in association with imaging and clinical outcomes. An observational retrospective cohort analysis was performed on 43 FFPE GBM tissue samples. MR images were assessed for the presence of hemorrhage and extent of resection. Specimens were examined for CD34 and CD105 expression using IHC. Tumor mRNA expression profiles were analyzed for 92 genes related to angiogenesis and vascularity. Forty-three specimens were analyzed, and 20 showed signs of hemorrhage, 23 did not. The average OS for patients with GBM with hemorrhage was 19.12 months (95{\%} CI 10.39–27.84), versus 13.85 months (95{\%} CI 8.85–18.85) in those without hemorrhage (p > 0.05). Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3. Hemorrhage in GBM was not associated with worsened OS. Increased expression of angiogenic factors and increased CD34 and CD105 IHC staining in tumors with hemorrhage suggests that increased hypoxia-induced angiogenesis and vessel density may play a role in glioblastoma hemorrhage. Characterizing tumors that are prone to hemorrhage and mechanisms behind the development of these hemorrhages may provide insights that can lead to the development of targeted, individualized therapies for glioblastoma.",
keywords = "Gene analysis, Glioblastoma, HIF1α, Hemorrhage, Vascularity",
author = "McGahan, {Ben G.} and Neilsen, {Beth K.} and Kelly, {David Lee} and McComb, {Rodney D} and Kazmi, {S. A Jaffar} and White, {Matthew L} and Yan Zhang and {Aizenberg Ansari}, {Michele R}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s11060-016-2350-3",
language = "English (US)",
volume = "132",
pages = "35--44",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Assessment of vascularity in glioblastoma and its implications on patient outcomes

AU - McGahan, Ben G.

AU - Neilsen, Beth K.

AU - Kelly, David Lee

AU - McComb, Rodney D

AU - Kazmi, S. A Jaffar

AU - White, Matthew L

AU - Zhang, Yan

AU - Aizenberg Ansari, Michele R

PY - 2017/3/1

Y1 - 2017/3/1

N2 - There is little data on why glioblastomas (GBM) hemorrhage and how it may affect patient outcomes. The aim of this study was to investigate the mechanisms of hemorrhage in glioblastoma by examining molecular and genetic features by immunohistochemistry (IHC) and mRNA expression profiles in association with imaging and clinical outcomes. An observational retrospective cohort analysis was performed on 43 FFPE GBM tissue samples. MR images were assessed for the presence of hemorrhage and extent of resection. Specimens were examined for CD34 and CD105 expression using IHC. Tumor mRNA expression profiles were analyzed for 92 genes related to angiogenesis and vascularity. Forty-three specimens were analyzed, and 20 showed signs of hemorrhage, 23 did not. The average OS for patients with GBM with hemorrhage was 19.12 months (95% CI 10.39–27.84), versus 13.85 months (95% CI 8.85–18.85) in those without hemorrhage (p > 0.05). Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3. Hemorrhage in GBM was not associated with worsened OS. Increased expression of angiogenic factors and increased CD34 and CD105 IHC staining in tumors with hemorrhage suggests that increased hypoxia-induced angiogenesis and vessel density may play a role in glioblastoma hemorrhage. Characterizing tumors that are prone to hemorrhage and mechanisms behind the development of these hemorrhages may provide insights that can lead to the development of targeted, individualized therapies for glioblastoma.

AB - There is little data on why glioblastomas (GBM) hemorrhage and how it may affect patient outcomes. The aim of this study was to investigate the mechanisms of hemorrhage in glioblastoma by examining molecular and genetic features by immunohistochemistry (IHC) and mRNA expression profiles in association with imaging and clinical outcomes. An observational retrospective cohort analysis was performed on 43 FFPE GBM tissue samples. MR images were assessed for the presence of hemorrhage and extent of resection. Specimens were examined for CD34 and CD105 expression using IHC. Tumor mRNA expression profiles were analyzed for 92 genes related to angiogenesis and vascularity. Forty-three specimens were analyzed, and 20 showed signs of hemorrhage, 23 did not. The average OS for patients with GBM with hemorrhage was 19.12 months (95% CI 10.39–27.84), versus 13.85 months (95% CI 8.85–18.85) in those without hemorrhage (p > 0.05). Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3. Hemorrhage in GBM was not associated with worsened OS. Increased expression of angiogenic factors and increased CD34 and CD105 IHC staining in tumors with hemorrhage suggests that increased hypoxia-induced angiogenesis and vessel density may play a role in glioblastoma hemorrhage. Characterizing tumors that are prone to hemorrhage and mechanisms behind the development of these hemorrhages may provide insights that can lead to the development of targeted, individualized therapies for glioblastoma.

KW - Gene analysis

KW - Glioblastoma

KW - HIF1α

KW - Hemorrhage

KW - Vascularity

UR - http://www.scopus.com/inward/record.url?scp=85009841559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009841559&partnerID=8YFLogxK

U2 - 10.1007/s11060-016-2350-3

DO - 10.1007/s11060-016-2350-3

M3 - Article

VL - 132

SP - 35

EP - 44

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -